drugset / Trial / NCT06537999
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN).
Timeline
- Start
- 2024-09-17
- Primary completion
- 2026-06-30
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Claseprubart | Unknown | 300 mg | Intravenous |
| Subject | Claseprubart | Unknown | 600 mg | Intravenous |